Breath test for detection of lung cancer

Details Breath test for detection of lung cancer Breath test for detection of lung cancer

1999-10-01

2001-11-06

Winakur, Eric F. (Department: 3736)

Surgery

Diagnostic testing

Respiratory

C436S064000, C128S206290, C128S898000

Reexamination Certificate

active

06312390

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to methods of detecting and diagnosing lung cancers in mammals.
2. Brief Description of Related Art
Primary carcinoma of the lung is the leading cause of cancer death in the United States. Every year, more than 100,000 males and 50,000 females develop lung cancer, and most of them die within twelve months. There is a clinical need for a screening test which can detect lung cancer in its earliest stages because prompt treatment of localized disease improves the 5-year survival rate to 30% in males and 50% in females. However, most cases are not detected until local or metastatic growth causes symptoms, and prospective screening with frequent radiography and sputum cytology has not improved the survival rate in smoking males aged 45 years or older. Since early detection of lung cancer can potentially reduce mortality, researchers have investigated alternative diagnostic technologies such as breath testing.
The rationale of a breath test for lung cancer is based upon three observations: first, carcinogenesis is accompanied by increased production of oxygen free radicals (OFRs), second, OFRs degrade cell membranes by lipid peroxidation, evolving alkanes such as ethane and pentane, and third, these alkanes are volatile organic compounds (VOCs) which are excreted in the breath.
OFRs cause mutagenesis by oxidative damage to DNA; as a result, affected cells acquire malignant properties and tumor clones expand. The mutagenic effects of OFRs appear to be partially reversible; treatment with OFR scavengers significantly improved survival in metastatic gastric cancer as well as in a rat model of colon cancer induced by 1,2-dimethylhydrazine. Oxidative stress has also been associated with chemical toxicity, ischemia, inflammation and dietary deficiency of antioxidants. The final common pathway is the intracellular accumulation of OFRs which overcome cellular defense mechanisms and degrade cellular membranes by lipid peroxidation, resulting in chemical and anatomical disruption of the membranes which may progress to cell death.
Breath hydrocarbons, particularly alkanes such as pentane, are markers of oxidative stress mediated by OFRs. Increased breath pentane has been reported in breast cancer, acute myocardial infarction, heart transplant rejection, rheumatoid arthritis, and acute bronchial asthma. Previous studies have attempted to identify the VOCs in breath which might provide clinically useful markers of lung cancer. Gordon et al reported 28 VOCs which were present in the breath of more than 90% of patients with lung cancer; and Preti et al found increased o-toluidine;
Preti G, Labows J N, Kostelc J G and Aldinger S: Analysis of lung air from patients with bronchogenic carcinoma and controls using gas chromatography mass spectrometry. J. Chromatography 1988;432:1-11.
Gordon S M, Szidon J P, Krotoszynski B K, Gibbons R D and O'Neill H J: Volatile organic compounds in exhaled air from patients with lung cancer. Clin Chem 1985; 31:1278-82;
O'Neill H J, Gordon S M, O'Neill MH, Gibbons R D and Szidon J P: A computerized classification technique for screening for the presence of breath biomarkers in lung cancer. Clin Chem 1988; 34(8):1613-1618.
However, progress in breath testing for lung cancer has been impeded by the technical difficulty of detecting VOCs in breath. The majority are excreted in very low concentrations: nanomolar (10
−9
mol/l) or picomolar (10
−12
mol/l). Most existing laboratory instruments cannot detect VOCs in such low levels in breath unless the sample is concentrated prior to analysis. Researchers have circumvented this problem by constructing specialized instruments for the collection and concentration of breath samples. Phillips has recently described a method for the collection and analysis of breath VOC samples which can be employed in clinical settings. A portable microprocessor-controlled breath collection apparatus collects alveolar breath VOCs onto sorbent traps which are then analyzed by conventional gas chromatography and mass spectroscopy. This breath collection apparatus was utilized to collect samples from patients undergoing bronchoscopy and biopsy for suspected lung cancer, in order to correlate the VOCs in alveolar breath with the histopathologic screening tests.
Phillips M: Method for the collection and assay of volatile organic compounds in breath. Analytical Biochemistry 1997;247:272-278.
SUMMARY OF THE INVENTION
The invention comprises a method of detecting and diagnosing lung cancer in a mammal, including a human, which comprises;
collecting a measured quantity of alveolar breath from the mammal; and
analyzing the collected breath for the presence of volatile organic markers for lung cancer;
the detection of volatile organic markers being indicative of the presence of a lung cancer screening test.
The test method is simple, non-invasive and economical as a screening test procedure.


REFERENCES:
patent: 4534360 (1985-08-01), Williams
patent: 4772559 (1988-09-01), Preti et al.
patent: 5465728 (1995-11-01), Phillips
patent: 5996586 (1999-12-01), Phillips

Affiliated with

Also associated with

Rating

Breath test for detection of lung cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Breath test for detection of lung cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breath test for detection of lung cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2574406